nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—RET—autonomic nervous system—rectum cancer	0.0131	0.0265	CbGeAlD
Ruxolitinib—PRKG2—smooth muscle tissue—rectum cancer	0.0074	0.015	CbGeAlD
Ruxolitinib—PRKG2—renal system—rectum cancer	0.00713	0.0145	CbGeAlD
Ruxolitinib—CAMK1—seminal vesicle—rectum cancer	0.00619	0.0126	CbGeAlD
Ruxolitinib—PLK1—mammalian vulva—rectum cancer	0.00598	0.0121	CbGeAlD
Ruxolitinib—PRKCE—female reproductive system—rectum cancer	0.00533	0.0108	CbGeAlD
Ruxolitinib—PLK3—urethra—rectum cancer	0.00524	0.0106	CbGeAlD
Ruxolitinib—RPS6KA6—female reproductive system—rectum cancer	0.00512	0.0104	CbGeAlD
Ruxolitinib—PLK1—female reproductive system—rectum cancer	0.00512	0.0104	CbGeAlD
Ruxolitinib—JAK1—seminal vesicle—rectum cancer	0.00508	0.0103	CbGeAlD
Ruxolitinib—PLK3—mammalian vulva—rectum cancer	0.00499	0.0101	CbGeAlD
Ruxolitinib—CAMK1—urethra—rectum cancer	0.0049	0.00995	CbGeAlD
Ruxolitinib—DAPK2—seminal vesicle—rectum cancer	0.00485	0.00984	CbGeAlD
Ruxolitinib—CAMK1—mammalian vulva—rectum cancer	0.00467	0.00947	CbGeAlD
Ruxolitinib—CLK2—seminal vesicle—rectum cancer	0.00451	0.00916	CbGeAlD
Ruxolitinib—JAK1—epithelium—rectum cancer	0.00441	0.00896	CbGeAlD
Ruxolitinib—TAOK2—urethra—rectum cancer	0.0044	0.00894	CbGeAlD
Ruxolitinib—DCLK3—vagina—rectum cancer	0.00439	0.00891	CbGeAlD
Ruxolitinib—PLK3—female reproductive system—rectum cancer	0.00427	0.00867	CbGeAlD
Ruxolitinib—JAK1—smooth muscle tissue—rectum cancer	0.00425	0.00863	CbGeAlD
Ruxolitinib—LTK—female reproductive system—rectum cancer	0.00413	0.00838	CbGeAlD
Ruxolitinib—JAK1—renal system—rectum cancer	0.00409	0.00831	CbGeAlD
Ruxolitinib—NUAK2—seminal vesicle—rectum cancer	0.00406	0.00824	CbGeAlD
Ruxolitinib—JAK1—urethra—rectum cancer	0.00402	0.00816	CbGeAlD
Ruxolitinib—DCLK1—urethra—rectum cancer	0.00402	0.00816	CbGeAlD
Ruxolitinib—CAMK1—female reproductive system—rectum cancer	0.004	0.00811	CbGeAlD
Ruxolitinib—CAMK1D—urethra—rectum cancer	0.00392	0.00797	CbGeAlD
Ruxolitinib—MARK2—female reproductive system—rectum cancer	0.00388	0.00788	CbGeAlD
Ruxolitinib—PLK3—vagina—rectum cancer	0.00386	0.00785	CbGeAlD
Ruxolitinib—DAPK2—urethra—rectum cancer	0.00384	0.00779	CbGeAlD
Ruxolitinib—JAK1—mammalian vulva—rectum cancer	0.00383	0.00777	CbGeAlD
Ruxolitinib—DCLK1—mammalian vulva—rectum cancer	0.00383	0.00777	CbGeAlD
Ruxolitinib—HIPK2—renal system—rectum cancer	0.00382	0.00776	CbGeAlD
Ruxolitinib—DAPK3—smooth muscle tissue—rectum cancer	0.00381	0.00774	CbGeAlD
Ruxolitinib—ROCK1—epithelium—rectum cancer	0.0038	0.00772	CbGeAlD
Ruxolitinib—LRRK2—seminal vesicle—rectum cancer	0.00377	0.00765	CbGeAlD
Ruxolitinib—CAMK1D—mammalian vulva—rectum cancer	0.00374	0.00759	CbGeAlD
Ruxolitinib—DAPK3—renal system—rectum cancer	0.00367	0.00745	CbGeAlD
Ruxolitinib—ROCK1—smooth muscle tissue—rectum cancer	0.00366	0.00743	CbGeAlD
Ruxolitinib—DAPK2—mammalian vulva—rectum cancer	0.00365	0.00741	CbGeAlD
Ruxolitinib—CLK2—renal system—rectum cancer	0.00364	0.00738	CbGeAlD
Ruxolitinib—CAMK1—vagina—rectum cancer	0.00361	0.00734	CbGeAlD
Ruxolitinib—DAPK3—urethra—rectum cancer	0.00361	0.00732	CbGeAlD
Ruxolitinib—CLK2—urethra—rectum cancer	0.00357	0.00725	CbGeAlD
Ruxolitinib—BMPR2—smooth muscle tissue—rectum cancer	0.00356	0.00722	CbGeAlD
Ruxolitinib—ROCK1—renal system—rectum cancer	0.00352	0.00716	CbGeAlD
Ruxolitinib—DYRK1A—renal system—rectum cancer	0.00344	0.00698	CbGeAlD
Ruxolitinib—DAPK3—mammalian vulva—rectum cancer	0.00343	0.00697	CbGeAlD
Ruxolitinib—BMPR2—renal system—rectum cancer	0.00342	0.00695	CbGeAlD
Ruxolitinib—MAP3K7—seminal vesicle—rectum cancer	0.00342	0.00694	CbGeAlD
Ruxolitinib—CLK2—mammalian vulva—rectum cancer	0.0034	0.00691	CbGeAlD
Ruxolitinib—BMPR2—urethra—rectum cancer	0.00336	0.00683	CbGeAlD
Ruxolitinib—TYK2—seminal vesicle—rectum cancer	0.00336	0.00682	CbGeAlD
Ruxolitinib—MKNK2—seminal vesicle—rectum cancer	0.00332	0.00673	CbGeAlD
Ruxolitinib—JAK3—female reproductive system—rectum cancer	0.0033	0.0067	CbGeAlD
Ruxolitinib—JAK1—female reproductive system—rectum cancer	0.00328	0.00666	CbGeAlD
Ruxolitinib—PLK4—female reproductive system—rectum cancer	0.00326	0.00661	CbGeAlD
Ruxolitinib—TAOK2—vagina—rectum cancer	0.00325	0.00659	CbGeAlD
Ruxolitinib—PHKG2—female reproductive system—rectum cancer	0.00318	0.00646	CbGeAlD
Ruxolitinib—PRKCE—lymph node—rectum cancer	0.00312	0.00633	CbGeAlD
Ruxolitinib—STK16—female reproductive system—rectum cancer	0.00308	0.00625	CbGeAlD
Ruxolitinib—HIPK2—female reproductive system—rectum cancer	0.00306	0.00621	CbGeAlD
Ruxolitinib—NUAK2—mammalian vulva—rectum cancer	0.00306	0.00621	CbGeAlD
Ruxolitinib—JAK2—seminal vesicle—rectum cancer	0.00306	0.0062	CbGeAlD
Ruxolitinib—LRRK2—renal system—rectum cancer	0.00304	0.00617	CbGeAlD
Ruxolitinib—CAMK2G—urethra—rectum cancer	0.00301	0.00611	CbGeAlD
Ruxolitinib—MAP3K19—female reproductive system—rectum cancer	0.003	0.00609	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—rectum cancer	0.00299	0.00608	CbGeAlD
Ruxolitinib—PLK1—lymph node—rectum cancer	0.00299	0.00608	CbGeAlD
Ruxolitinib—LRRK2—urethra—rectum cancer	0.00298	0.00606	CbGeAlD
Ruxolitinib—JAK1—vagina—rectum cancer	0.00296	0.00602	CbGeAlD
Ruxolitinib—DCLK1—vagina—rectum cancer	0.00296	0.00602	CbGeAlD
Ruxolitinib—MAP3K3—seminal vesicle—rectum cancer	0.00295	0.00598	CbGeAlD
Ruxolitinib—DAPK3—female reproductive system—rectum cancer	0.00294	0.00597	CbGeAlD
Ruxolitinib—CLK2—female reproductive system—rectum cancer	0.00291	0.00591	CbGeAlD
Ruxolitinib—CAMK1D—vagina—rectum cancer	0.00289	0.00587	CbGeAlD
Ruxolitinib—MKNK2—epithelium—rectum cancer	0.00288	0.00585	CbGeAlD
Ruxolitinib—MAP3K7—smooth muscle tissue—rectum cancer	0.00286	0.00581	CbGeAlD
Ruxolitinib—LRRK2—mammalian vulva—rectum cancer	0.00284	0.00577	CbGeAlD
Ruxolitinib—DAPK2—vagina—rectum cancer	0.00283	0.00574	CbGeAlD
Ruxolitinib—ROCK1—female reproductive system—rectum cancer	0.00282	0.00573	CbGeAlD
Ruxolitinib—TYK2—smooth muscle tissue—rectum cancer	0.00281	0.00571	CbGeAlD
Ruxolitinib—RET—epithelium—rectum cancer	0.00281	0.0057	CbGeAlD
Ruxolitinib—STK16—vagina—rectum cancer	0.00278	0.00565	CbGeAlD
Ruxolitinib—IRAK1—smooth muscle tissue—rectum cancer	0.00278	0.00563	CbGeAlD
Ruxolitinib—MKNK2—smooth muscle tissue—rectum cancer	0.00278	0.00563	CbGeAlD
Ruxolitinib—DYRK1A—female reproductive system—rectum cancer	0.00275	0.00559	CbGeAlD
Ruxolitinib—BMPR2—female reproductive system—rectum cancer	0.00274	0.00557	CbGeAlD
Ruxolitinib—MAP3K7—urethra—rectum cancer	0.00271	0.0055	CbGeAlD
Ruxolitinib—TYK2—renal system—rectum cancer	0.00271	0.00549	CbGeAlD
Ruxolitinib—TAOK3—seminal vesicle—rectum cancer	0.00269	0.00545	CbGeAlD
Ruxolitinib—MKNK2—renal system—rectum cancer	0.00267	0.00542	CbGeAlD
Ruxolitinib—DAPK3—vagina—rectum cancer	0.00266	0.0054	CbGeAlD
Ruxolitinib—TYK2—urethra—rectum cancer	0.00266	0.0054	CbGeAlD
Ruxolitinib—JAK2—epithelium—rectum cancer	0.00265	0.00539	CbGeAlD
Ruxolitinib—CLK2—vagina—rectum cancer	0.00263	0.00535	CbGeAlD
Ruxolitinib—MKNK2—urethra—rectum cancer	0.00262	0.00533	CbGeAlD
Ruxolitinib—RET—renal system—rectum cancer	0.00261	0.00529	CbGeAlD
Ruxolitinib—MAP3K7—mammalian vulva—rectum cancer	0.00258	0.00523	CbGeAlD
Ruxolitinib—JAK2—smooth muscle tissue—rectum cancer	0.00256	0.00519	CbGeAlD
Ruxolitinib—TYK2—mammalian vulva—rectum cancer	0.00253	0.00514	CbGeAlD
Ruxolitinib—PLK3—lymph node—rectum cancer	0.0025	0.00507	CbGeAlD
Ruxolitinib—IRAK1—mammalian vulva—rectum cancer	0.0025	0.00507	CbGeAlD
Ruxolitinib—MKNK2—mammalian vulva—rectum cancer	0.0025	0.00507	CbGeAlD
Ruxolitinib—BMPR2—vagina—rectum cancer	0.00248	0.00504	CbGeAlD
Ruxolitinib—JAK2—renal system—rectum cancer	0.00246	0.005	CbGeAlD
Ruxolitinib—CAMK2G—female reproductive system—rectum cancer	0.00245	0.00498	CbGeAlD
Ruxolitinib—BMP2K—female reproductive system—rectum cancer	0.00245	0.00498	CbGeAlD
Ruxolitinib—LRRK2—female reproductive system—rectum cancer	0.00243	0.00494	CbGeAlD
Ruxolitinib—JAK2—urethra—rectum cancer	0.00242	0.00491	CbGeAlD
Ruxolitinib—LTK—lymph node—rectum cancer	0.00241	0.0049	CbGeAlD
Ruxolitinib—NUAK2—vagina—rectum cancer	0.00237	0.00481	CbGeAlD
Ruxolitinib—CAMK1—lymph node—rectum cancer	0.00234	0.00475	CbGeAlD
Ruxolitinib—MAP3K3—urethra—rectum cancer	0.00233	0.00473	CbGeAlD
Ruxolitinib—JAK2—mammalian vulva—rectum cancer	0.0023	0.00468	CbGeAlD
Ruxolitinib—MARK2—lymph node—rectum cancer	0.00227	0.00461	CbGeAlD
Ruxolitinib—MAP3K2—female reproductive system—rectum cancer	0.00223	0.00452	CbGeAlD
Ruxolitinib—MAP3K3—mammalian vulva—rectum cancer	0.00222	0.00451	CbGeAlD
Ruxolitinib—BMP2K—vagina—rectum cancer	0.00222	0.00451	CbGeAlD
Ruxolitinib—CAMK2G—vagina—rectum cancer	0.00222	0.00451	CbGeAlD
Ruxolitinib—LRRK2—vagina—rectum cancer	0.0022	0.00447	CbGeAlD
Ruxolitinib—TYK2—female reproductive system—rectum cancer	0.00217	0.0044	CbGeAlD
Ruxolitinib—TAOK3—renal system—rectum cancer	0.00216	0.00439	CbGeAlD
Ruxolitinib—MKNK2—female reproductive system—rectum cancer	0.00214	0.00434	CbGeAlD
Ruxolitinib—IRAK1—female reproductive system—rectum cancer	0.00214	0.00434	CbGeAlD
Ruxolitinib—TAOK3—urethra—rectum cancer	0.00213	0.00432	CbGeAlD
Ruxolitinib—TAOK2—lymph node—rectum cancer	0.0021	0.00426	CbGeAlD
Ruxolitinib—TAOK3—mammalian vulva—rectum cancer	0.00202	0.00411	CbGeAlD
Ruxolitinib—MAP3K7—vagina—rectum cancer	0.002	0.00405	CbGeAlD
Ruxolitinib—JAK2—female reproductive system—rectum cancer	0.00197	0.004	CbGeAlD
Ruxolitinib—TYK2—vagina—rectum cancer	0.00196	0.00398	CbGeAlD
Ruxolitinib—MKNK2—vagina—rectum cancer	0.00193	0.00393	CbGeAlD
Ruxolitinib—JAK3—lymph node—rectum cancer	0.00193	0.00392	CbGeAlD
Ruxolitinib—JAK1—lymph node—rectum cancer	0.00192	0.00389	CbGeAlD
Ruxolitinib—DCLK1—lymph node—rectum cancer	0.00192	0.00389	CbGeAlD
Ruxolitinib—PLK4—lymph node—rectum cancer	0.00191	0.00387	CbGeAlD
Ruxolitinib—MAP3K3—female reproductive system—rectum cancer	0.0019	0.00386	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—rectum cancer	0.00187	0.0038	CbGeAlD
Ruxolitinib—PHKG2—lymph node—rectum cancer	0.00186	0.00378	CbGeAlD
Ruxolitinib—DAPK2—lymph node—rectum cancer	0.00183	0.00371	CbGeAlD
Ruxolitinib—STK16—lymph node—rectum cancer	0.0018	0.00365	CbGeAlD
Ruxolitinib—HIPK2—lymph node—rectum cancer	0.00179	0.00363	CbGeAlD
Ruxolitinib—JAK2—vagina—rectum cancer	0.00178	0.00362	CbGeAlD
Ruxolitinib—TAOK3—female reproductive system—rectum cancer	0.00173	0.00352	CbGeAlD
Ruxolitinib—DAPK3—lymph node—rectum cancer	0.00172	0.00349	CbGeAlD
Ruxolitinib—MAP3K3—vagina—rectum cancer	0.00172	0.00349	CbGeAlD
Ruxolitinib—CLK2—lymph node—rectum cancer	0.0017	0.00346	CbGeAlD
Ruxolitinib—DYRK1A—lymph node—rectum cancer	0.00161	0.00327	CbGeAlD
Ruxolitinib—BMPR2—lymph node—rectum cancer	0.0016	0.00326	CbGeAlD
Ruxolitinib—TAOK3—vagina—rectum cancer	0.00157	0.00318	CbGeAlD
Ruxolitinib—NUAK2—lymph node—rectum cancer	0.00153	0.00311	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—rectum cancer	0.00144	0.00291	CbGeAlD
Ruxolitinib—BMP2K—lymph node—rectum cancer	0.00144	0.00291	CbGeAlD
Ruxolitinib—LRRK2—lymph node—rectum cancer	0.00142	0.00289	CbGeAlD
Ruxolitinib—MAP3K2—lymph node—rectum cancer	0.0013	0.00265	CbGeAlD
Ruxolitinib—MAP3K7—lymph node—rectum cancer	0.00129	0.00262	CbGeAlD
Ruxolitinib—TYK2—lymph node—rectum cancer	0.00127	0.00257	CbGeAlD
Ruxolitinib—MKNK2—lymph node—rectum cancer	0.00125	0.00254	CbGeAlD
Ruxolitinib—IRAK1—lymph node—rectum cancer	0.00125	0.00254	CbGeAlD
Ruxolitinib—RET—lymph node—rectum cancer	0.00122	0.00248	CbGeAlD
Ruxolitinib—JAK2—lymph node—rectum cancer	0.00115	0.00234	CbGeAlD
Ruxolitinib—MAP3K3—lymph node—rectum cancer	0.00111	0.00226	CbGeAlD
Ruxolitinib—TAOK3—lymph node—rectum cancer	0.00101	0.00206	CbGeAlD
Ruxolitinib—CYP3A4—renal system—rectum cancer	0.000657	0.00133	CbGeAlD
Ruxolitinib—CYP3A4—female reproductive system—rectum cancer	0.000526	0.00107	CbGeAlD
Ruxolitinib—JAK2—Signaling by Insulin receptor—HRAS—rectum cancer	0.000163	0.000321	CbGpPWpGaD
Ruxolitinib—MAP3K7—MAPK Signaling Pathway—TP53—rectum cancer	0.000162	0.00032	CbGpPWpGaD
Ruxolitinib—MAP3K7—B Cell Activation—KRAS—rectum cancer	0.000162	0.000319	CbGpPWpGaD
Ruxolitinib—MAP3K7—Insulin Signaling—HRAS—rectum cancer	0.000161	0.000318	CbGpPWpGaD
Ruxolitinib—TYK2—NGF signalling via TRKA from the plasma membrane—KRAS—rectum cancer	0.00016	0.000315	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR in disease—NRAS—rectum cancer	0.000159	0.000313	CbGpPWpGaD
Ruxolitinib—JAK2—Fc epsilon receptor (FCERI) signaling—NRAS—rectum cancer	0.000159	0.000313	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 interactions—NRAS—rectum cancer	0.000159	0.000313	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR—NRAS—rectum cancer	0.000158	0.000311	CbGpPWpGaD
Ruxolitinib—JAK2—Downstream signaling of activated FGFR—KRAS—rectum cancer	0.000157	0.00031	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR in Cancer—NRAS—rectum cancer	0.000156	0.000308	CbGpPWpGaD
Ruxolitinib—MAP3K7—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000156	0.000307	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by PDGF—NRAS—rectum cancer	0.000155	0.000306	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by ERBB4—KRAS—rectum cancer	0.000155	0.000305	CbGpPWpGaD
Ruxolitinib—TYK2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—rectum cancer	0.000155	0.000305	CbGpPWpGaD
Ruxolitinib—JAK2—PDGFR-beta signaling pathway—HRAS—rectum cancer	0.000154	0.000303	CbGpPWpGaD
Ruxolitinib—TYK2—Fc epsilon receptor (FCERI) signaling—HRAS—rectum cancer	0.000153	0.000302	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by FGFR in disease—HRAS—rectum cancer	0.000153	0.000302	CbGpPWpGaD
Ruxolitinib—TYK2—DAP12 interactions—HRAS—rectum cancer	0.000153	0.000302	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by EGFR—HRAS—rectum cancer	0.000152	0.0003	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—NRAS—rectum cancer	0.000152	0.0003	CbGpPWpGaD
Ruxolitinib—JAK1—Axon guidance—KRAS—rectum cancer	0.000151	0.000297	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by EGFR in Cancer—HRAS—rectum cancer	0.000151	0.000297	CbGpPWpGaD
Ruxolitinib—JAK2—Factors involved in megakaryocyte development and platelet production—TP53—rectum cancer	0.00015	0.000296	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by PDGF—HRAS—rectum cancer	0.00015	0.000296	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—NRAS—rectum cancer	0.00015	0.000295	CbGpPWpGaD
Ruxolitinib—MAP3K7—Fc epsilon receptor (FCERI) signaling—HRAS—rectum cancer	0.000149	0.000293	CbGpPWpGaD
Ruxolitinib—ROCK1—Axon guidance—KRAS—rectum cancer	0.000148	0.000292	CbGpPWpGaD
Ruxolitinib—JAK2—Downstream signal transduction—KRAS—rectum cancer	0.000148	0.000291	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—NRAS—rectum cancer	0.000147	0.00029	CbGpPWpGaD
Ruxolitinib—JAK2—EGF/EGFR Signaling Pathway—KRAS—rectum cancer	0.000147	0.000289	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR—KRAS—rectum cancer	0.000147	0.000289	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by ERBB2—KRAS—rectum cancer	0.000146	0.000288	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 signaling—KRAS—rectum cancer	0.000145	0.000287	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—KRAS—rectum cancer	0.000145	0.000287	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—NRAS—rectum cancer	0.000145	0.000286	CbGpPWpGaD
Ruxolitinib—JAK1—Cytokine Signaling in Immune system—HRAS—rectum cancer	0.000144	0.000284	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—NRAS—rectum cancer	0.000143	0.000282	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—NRAS—rectum cancer	0.000143	0.000281	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by NGF—HRAS—rectum cancer	0.000142	0.000279	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—NRAS—rectum cancer	0.000141	0.000278	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—NRAS—rectum cancer	0.000141	0.000278	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by SCF-KIT—HRAS—rectum cancer	0.00014	0.000275	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—NRAS—rectum cancer	0.000139	0.000275	CbGpPWpGaD
Ruxolitinib—MAP3K7—B Cell Activation—HRAS—rectum cancer	0.000138	0.000271	CbGpPWpGaD
Ruxolitinib—JAK2—BDNF signaling pathway—HRAS—rectum cancer	0.000137	0.00027	CbGpPWpGaD
Ruxolitinib—JAK2—Fc epsilon receptor (FCERI) signaling—KRAS—rectum cancer	0.000137	0.00027	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 interactions—KRAS—rectum cancer	0.000137	0.00027	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR in disease—KRAS—rectum cancer	0.000137	0.00027	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—rectum cancer	0.000136	0.000268	CbGpPWpGaD
Ruxolitinib—TYK2—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.000136	0.000268	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR—KRAS—rectum cancer	0.000136	0.000267	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR in Cancer—KRAS—rectum cancer	0.000134	0.000265	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle—TP53—rectum cancer	0.000134	0.000264	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by PDGF—KRAS—rectum cancer	0.000134	0.000264	CbGpPWpGaD
Ruxolitinib—JAK2—Downstream signaling of activated FGFR—HRAS—rectum cancer	0.000133	0.000263	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by ERBB4—HRAS—rectum cancer	0.000131	0.000259	CbGpPWpGaD
Ruxolitinib—TYK2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—rectum cancer	0.000131	0.000259	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—KRAS—rectum cancer	0.000131	0.000258	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—NRAS—rectum cancer	0.000129	0.000255	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—TP53—rectum cancer	0.000129	0.000255	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—KRAS—rectum cancer	0.000129	0.000254	CbGpPWpGaD
Ruxolitinib—JAK1—Axon guidance—HRAS—rectum cancer	0.000128	0.000253	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—KRAS—rectum cancer	0.000127	0.00025	CbGpPWpGaD
Ruxolitinib—ROCK1—Axon guidance—HRAS—rectum cancer	0.000126	0.000248	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—NRAS—rectum cancer	0.000126	0.000248	CbGpPWpGaD
Ruxolitinib—JAK2—Downstream signal transduction—HRAS—rectum cancer	0.000125	0.000247	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—KRAS—rectum cancer	0.000125	0.000247	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—NRAS—rectum cancer	0.000125	0.000246	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR—HRAS—rectum cancer	0.000125	0.000246	CbGpPWpGaD
Ruxolitinib—JAK2—EGF/EGFR Signaling Pathway—HRAS—rectum cancer	0.000125	0.000246	CbGpPWpGaD
Ruxolitinib—PLK4—Cell Cycle—TP53—rectum cancer	0.000125	0.000246	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by ERBB2—HRAS—rectum cancer	0.000124	0.000245	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 signaling—HRAS—rectum cancer	0.000124	0.000244	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—HRAS—rectum cancer	0.000124	0.000244	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—KRAS—rectum cancer	0.000123	0.000242	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—NRAS—rectum cancer	0.000123	0.000242	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—KRAS—rectum cancer	0.000123	0.000242	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—NRAS—rectum cancer	0.000123	0.000242	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—KRAS—rectum cancer	0.000121	0.000239	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—KRAS—rectum cancer	0.000121	0.000239	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—KRAS—rectum cancer	0.00012	0.000236	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—rectum cancer	0.000117	0.000231	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR in disease—HRAS—rectum cancer	0.000116	0.000229	CbGpPWpGaD
Ruxolitinib—JAK2—Fc epsilon receptor (FCERI) signaling—HRAS—rectum cancer	0.000116	0.000229	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 interactions—HRAS—rectum cancer	0.000116	0.000229	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR—HRAS—rectum cancer	0.000115	0.000227	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR in Cancer—HRAS—rectum cancer	0.000114	0.000225	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by PDGF—HRAS—rectum cancer	0.000114	0.000224	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—KRAS—rectum cancer	0.000111	0.000219	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—HRAS—rectum cancer	0.000111	0.000219	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—NRAS—rectum cancer	0.00011	0.000218	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—NRAS—rectum cancer	0.00011	0.000217	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—HRAS—rectum cancer	0.00011	0.000216	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—TP53—rectum cancer	0.000109	0.000215	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—KRAS—rectum cancer	0.000108	0.000214	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—NRAS—rectum cancer	0.000108	0.000213	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—HRAS—rectum cancer	0.000108	0.000212	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—KRAS—rectum cancer	0.000108	0.000212	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—HRAS—rectum cancer	0.000106	0.00021	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—KRAS—rectum cancer	0.000106	0.000209	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—KRAS—rectum cancer	0.000106	0.000208	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—HRAS—rectum cancer	0.000105	0.000206	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—HRAS—rectum cancer	0.000104	0.000206	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—NRAS—rectum cancer	0.000104	0.000204	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—HRAS—rectum cancer	0.000103	0.000203	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.000103	0.000203	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—HRAS—rectum cancer	0.000102	0.000201	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—rectum cancer	9.96e-05	0.000196	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—NRAS—rectum cancer	9.8e-05	0.000193	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—NRAS—rectum cancer	9.75e-05	0.000192	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—NRAS—rectum cancer	9.69e-05	0.000191	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—KRAS—rectum cancer	9.5e-05	0.000187	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—KRAS—rectum cancer	9.48e-05	0.000187	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—HRAS—rectum cancer	9.46e-05	0.000186	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—TP53—rectum cancer	9.38e-05	0.000185	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—KRAS—rectum cancer	9.32e-05	0.000184	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—NRAS—rectum cancer	9.23e-05	0.000182	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—HRAS—rectum cancer	9.22e-05	0.000182	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—HRAS—rectum cancer	9.15e-05	0.00018	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—HRAS—rectum cancer	9e-05	0.000177	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—HRAS—rectum cancer	8.97e-05	0.000177	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—KRAS—rectum cancer	8.93e-05	0.000176	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—NRAS—rectum cancer	8.86e-05	0.000175	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—NRAS—rectum cancer	8.82e-05	0.000174	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—KRAS—rectum cancer	8.44e-05	0.000166	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—NRAS—rectum cancer	8.4e-05	0.000165	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—KRAS—rectum cancer	8.4e-05	0.000165	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—KRAS—rectum cancer	8.34e-05	0.000164	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—NRAS—rectum cancer	8.18e-05	0.000161	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—NRAS—rectum cancer	8.18e-05	0.000161	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—NRAS—rectum cancer	8.15e-05	0.000161	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—NRAS—rectum cancer	8.11e-05	0.00016	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—HRAS—rectum cancer	8.08e-05	0.000159	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HRAS—rectum cancer	8.06e-05	0.000159	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—KRAS—rectum cancer	7.94e-05	0.000157	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—rectum cancer	7.94e-05	0.000156	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—NRAS—rectum cancer	7.93e-05	0.000156	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—HRAS—rectum cancer	7.92e-05	0.000156	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—NRAS—rectum cancer	7.91e-05	0.000156	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—KRAS—rectum cancer	7.62e-05	0.00015	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—KRAS—rectum cancer	7.59e-05	0.00015	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—NRAS—rectum cancer	7.59e-05	0.00015	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—HRAS—rectum cancer	7.59e-05	0.00015	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—NRAS—rectum cancer	7.48e-05	0.000147	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—rectum cancer	7.46e-05	0.000147	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—KRAS—rectum cancer	7.23e-05	0.000142	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—HRAS—rectum cancer	7.17e-05	0.000141	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—HRAS—rectum cancer	7.14e-05	0.000141	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—HRAS—rectum cancer	7.09e-05	0.00014	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—KRAS—rectum cancer	7.04e-05	0.000139	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—KRAS—rectum cancer	7.04e-05	0.000139	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—NRAS—rectum cancer	7.04e-05	0.000139	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—KRAS—rectum cancer	7.02e-05	0.000138	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—NRAS—rectum cancer	6.99e-05	0.000138	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—KRAS—rectum cancer	6.98e-05	0.000138	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—NRAS—rectum cancer	6.92e-05	0.000136	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—NRAS—rectum cancer	6.86e-05	0.000135	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—KRAS—rectum cancer	6.82e-05	0.000134	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—KRAS—rectum cancer	6.8e-05	0.000134	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—HRAS—rectum cancer	6.75e-05	0.000133	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—rectum cancer	6.75e-05	0.000133	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—KRAS—rectum cancer	6.53e-05	0.000129	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HRAS—rectum cancer	6.48e-05	0.000128	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—HRAS—rectum cancer	6.45e-05	0.000127	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—KRAS—rectum cancer	6.43e-05	0.000127	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—NRAS—rectum cancer	6.43e-05	0.000127	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—NRAS—rectum cancer	6.18e-05	0.000122	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—HRAS—rectum cancer	6.14e-05	0.000121	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—KRAS—rectum cancer	6.06e-05	0.000119	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—KRAS—rectum cancer	6.02e-05	0.000119	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—HRAS—rectum cancer	5.99e-05	0.000118	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—HRAS—rectum cancer	5.98e-05	0.000118	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HRAS—rectum cancer	5.96e-05	0.000118	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—KRAS—rectum cancer	5.96e-05	0.000117	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—NRAS—rectum cancer	5.94e-05	0.000117	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HRAS—rectum cancer	5.94e-05	0.000117	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—KRAS—rectum cancer	5.91e-05	0.000116	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HRAS—rectum cancer	5.8e-05	0.000114	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HRAS—rectum cancer	5.78e-05	0.000114	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—NRAS—rectum cancer	5.73e-05	0.000113	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HRAS—rectum cancer	5.55e-05	0.000109	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—KRAS—rectum cancer	5.54e-05	0.000109	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HRAS—rectum cancer	5.47e-05	0.000108	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—KRAS—rectum cancer	5.32e-05	0.000105	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—rectum cancer	5.25e-05	0.000103	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—NRAS—rectum cancer	5.2e-05	0.000102	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HRAS—rectum cancer	5.15e-05	0.000101	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—HRAS—rectum cancer	5.12e-05	0.000101	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—KRAS—rectum cancer	5.11e-05	0.000101	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HRAS—rectum cancer	5.06e-05	9.98e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—HRAS—rectum cancer	5.02e-05	9.89e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KRAS—rectum cancer	4.93e-05	9.71e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—NRAS—rectum cancer	4.89e-05	9.64e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NRAS—rectum cancer	4.83e-05	9.53e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NRAS—rectum cancer	4.75e-05	9.36e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HRAS—rectum cancer	4.7e-05	9.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NRAS—rectum cancer	4.6e-05	9.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HRAS—rectum cancer	4.52e-05	8.91e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—KRAS—rectum cancer	4.47e-05	8.81e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NRAS—rectum cancer	4.38e-05	8.64e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—rectum cancer	4.38e-05	8.63e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—rectum cancer	4.34e-05	8.56e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—rectum cancer	4.21e-05	8.3e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—rectum cancer	4.19e-05	8.26e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—rectum cancer	4.16e-05	8.2e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NRAS—rectum cancer	4.16e-05	8.19e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NRAS—rectum cancer	4.09e-05	8.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—rectum cancer	4.09e-05	8.05e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—rectum cancer	3.96e-05	7.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—NRAS—rectum cancer	3.94e-05	7.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—rectum cancer	3.8e-05	7.49e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—rectum cancer	3.77e-05	7.44e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—rectum cancer	3.7e-05	7.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRAS—rectum cancer	3.6e-05	7.09e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—rectum cancer	3.58e-05	7.05e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—rectum cancer	3.58e-05	7.05e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—rectum cancer	3.54e-05	6.97e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—rectum cancer	3.52e-05	6.94e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—rectum cancer	3.47e-05	6.84e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—rectum cancer	3.39e-05	6.68e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—rectum cancer	3.37e-05	6.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRAS—rectum cancer	3.32e-05	6.55e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—rectum cancer	3.21e-05	6.32e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—rectum cancer	3.18e-05	6.27e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRAS—rectum cancer	3.16e-05	6.23e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—rectum cancer	3.13e-05	6.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—rectum cancer	3.1e-05	6.1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRAS—rectum cancer	3.07e-05	6.05e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—rectum cancer	3.04e-05	5.99e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—rectum cancer	2.99e-05	5.9e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRAS—rectum cancer	2.98e-05	5.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—rectum cancer	2.88e-05	5.68e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—rectum cancer	2.86e-05	5.63e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—rectum cancer	2.72e-05	5.36e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—rectum cancer	2.64e-05	5.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—rectum cancer	2.63e-05	5.19e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—rectum cancer	2.56e-05	5.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—rectum cancer	2.43e-05	4.79e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—rectum cancer	2.42e-05	4.77e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—rectum cancer	2.35e-05	4.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRAS—rectum cancer	2.33e-05	4.58e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—rectum cancer	2.31e-05	4.56e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—rectum cancer	2.28e-05	4.49e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—rectum cancer	2.25e-05	4.43e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—rectum cancer	2.18e-05	4.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—rectum cancer	2e-05	3.95e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TYMS—rectum cancer	1.81e-05	3.57e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—rectum cancer	1.78e-05	3.51e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—rectum cancer	1.7e-05	3.35e-05	CbGpPWpGaD
